References

• UNODC, World Drug Report 2012 United Nations publication, Sales No. E.12.XI.1
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2010: The State of the Drugs Problem in Europe. Publications Office of the European Union, Luxembourg, 2010.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Office of Applied Studies Results from the 2009 National Survey on Drug Use and Health. Volume 1, 2010.
   Google Scholar
• Becker WC, Fiellin DA, Merrill JO, Schulman B, Finkelstein R, Olsen Y, Busch SH. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend 2008;94(1–3):207–13. [CrossRef]
   Web of Science ®Google Scholar
• Clausen T, Waal H, Thoresen M, Gossop M. Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction 2009;104(8):1356–62. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Shah NG, Lathrop SL, Reichard RR, Landen MG. Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. Addiction 2008;103(1):126–36. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Wisniewski AM, Purdy CH, Blondell RD. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. J Addict Dis 2008;27(1):1–11. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Strain EC. Pharmacology of buprenorphine. In The Treatment of Opioid Dependence, EC Strain, M L Stitzer (editors). Baltimore: Johns Hopkins Press, 2006, pp. 213–29.
   Google Scholar
• Helm S, Trescot AM, Colson J, Sehgal N, Silverman S. Opioid antagonists, partial agonists and agonists/antagonists: The role of office-based detoxification. Pain Physician 2008;11(2):225–35.
   Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technol Assess 2007;11(9):1–171 iii–iv.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;16(2):CD002207.
   Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS. Counseling plus buprenorphine-naloxone therapy for opioid dependence. N Engl J Med 2006;355(4):365–74. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP. Foreword to: buprenorphine and buprenorphine/naloxone: a guide for clinicians. Drug Alcohol Depend 2003;70(2 Suppl):S1-2. [CrossRef]
   Google Scholar
• Stein MD, Cioe P, Friedmann PD. Briefreport: Buprenorphine retention in primary care. J Gen Intern Med 2005:20(11): 1038–41. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Ministry of Health of the Republic of Turkey General Directorate of Pharmaceuticals and Pharmacy, 23 November 2009 and 079 661 (Circular 2009/74) and 14 October 2010 and numbered 070 068 (Circular 2010/72) of circulars. (Turkish)
   Google Scholar
• Evren C, Can Y, Mutlu E, Karabulut V, Ciftci-Demirci A, Umut G, et al. Suboxone (buprenorphine: naloxone) application guide. Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry, Neurology and Nerosurgery, AMATEM Clinic, February 2012. (Turkish)
   Google Scholar
• Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 2005;526 (1–3):36–50. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Armstrong G, Kermode M, Sharma C, Langkham B, Crofts N. Opioid substitution therapy in Manipur and Nagaland, North-East India: Operational research in action. Harm Reduct J 2010;7:29. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in communitybased primary care settings. Ann Fam Med 2007;5(2):146–50. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Zhang Z, Friedman PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003;98(5):673–84. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomized, placebo-controlled trial. Lancet 2003;361(9358):662–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Davoli M, Perucci CA, Forastiere F, Doyle P, Rapiti E, Zaccarelli M, Abeni DD. Risk factors for overdose mortality: A case-control study within a cohort of intravenous drug users. Int J Epidemiol 1993;22(2):273–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, Spire B. Retention in opioid substitution treatment: A major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009;49(9):1433–40. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Kakko J, Gronbladh L, Svanborg KD, von Wachenfeldt J, Ruck C, Rawlings B, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. Am J Psychiatry 2007;164(5):797–803. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, et al. Long-term treatment with buprehorphine/naloxone in primary care: Results at 2–5 years. Am J Addict 2008;17(2):116–20. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009;37(4):426–30. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010;39(4):340–52. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat 2012;43(4):451–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiatry 1991;15(4):531–8. [CrossRef]
   Web of Science ®Google Scholar
• Petry NM, Bickel WK. Therapeutic alliance and psychiatric severity as predictors of completion of treatment for opioid dependence. Psychiatr Serv 1999;50(2):219–27.
   PubMed Web of Science ®Google Scholar
• Petry NM, Bickel WK. Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination. Drug Alcohol Depend 2000;58(1–2):27–33. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Pani PP, Maremmani I, Pirastu R, Tagliamont A, Gessa, GL. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60(1):39–50. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine versus methadone-maintained patients. J Nerv Ment Dis 1998;186(1):35–43. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol 2005;13(4):293–302. [CrossRef]
   Web of Science ®Google Scholar
• Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. Int J Neuropsychopharmacol 2008;11(5):641–53. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict 2010;19(1):53–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Depend 2004;75(1):37–45. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Leonardi C, Hanna N, Laurenzi P, Fagetti R, I.D.A.C. Group. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug Alcohol Depend 2008;94(1–3):125–32. [CrossRef]
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Stuructured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinical Version. Washington D.C. and London. American Psychiatric Press, Inc, 1997.
   Google Scholar
• Corapcioglu A, Aydemir O, Yildiz M, Esen A, Koroglu E: DSM-IV Axis I Disorders (SCID-I) for the Structured Clinical Interview, Clinical Version. Ankara. Hekimler Yayın Birliği, 1999. (Turkish)
   Google Scholar
• Evren C, Yilmaz A, Evren B, Bozkurt M, Can Y. Factorial structure and reabilidity of Bakırköy Opioid Withdrawal Scale among heroin dependent patients. The 5th International Congress on Psychopharmacology & International Symposium on Child and Adolescent Psychopharmacology (TAP-ICP), October 30—November 3, Antalya, Turkey, p186–7. (Poster)
   Google Scholar
• Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999;23(8):1289–95. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Evren C, Flannery B, Çetin R, Durkaya M, Dalbudak E. Reliability and Validity of Turkish Version the Penn Alcohol Craving Scale (PACS) in Male Alcohol Dependent Inpatients. Journal of Dependence 2008;9(3):128–34. (Turkish)
   Google Scholar
• Evren C, Gurol DT, Ogel K, Karadag F. Reliability and validity of the Penn Alcohol Craving Scale (PACS) Revised Version for substance craving in male substance dependent inpatients. Turk Psikiyatri Derg 2011;22(Suppl. 1):70.
   Google Scholar
• Mdege ND, Lang J. Screening instruments for detecting illicit drug use/abuse that could be useful in general hospital wards: a systematic review. Addict Behav 2011;36(12):1111–9. [CrossRef]
   Web of Science ®Google Scholar
• Saunders J, Aasland O, Babor T, de la Fuente J, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT):WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993;88(6):791–804. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Berman A, Bergman H, Palmstierna T, Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res 2005;11(1):22–31. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Evren C, Ovalı E, Karabulut V, Cetingok S, Mutlu E. Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) with heroin dependent adults and adolescents with drug use disorder. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2014;24(1):39–48. [CrossRef]
   Web of Science ®Google Scholar
• Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat 2007;32(2):189–98. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Skinner H. The Drug Abuse Screening Test. Addict Behav 1982;7(4):363–71. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Gibbs LE. Validity and reliability of the Michigan Alcoholism Screening Test: A review. Drug Alcohol Depend 1985;12(3):279–85. [CrossRef]
   Web of Science ®Google Scholar
• Evren C, Ovalı E, Cetingok S, Karabulut V, Mutlu E. Psychometric properties of the Drug Abuse Screening Test (DAST-10) with heroin dependent adults and adolescents with drug use disorder. Dusunen Adam Journal of Psychiatry and Neurological Sciences 2013;26(4):351–9. [CrossRef]
   Google Scholar
• Miller WR, Tonigan JS. Assessing drinkers' motivation for change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychology Addict Behav 1996;10(2):81–9. [CrossRef]
   Web of Science ®Google Scholar
• Evren C, Dalbudak E, Çakmak D. Factorial structure and reliability and validity of Turkish Version the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES) in male alcohol dependent inpatients. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2008;18(2):84–91.
   Google Scholar
• Evren C, Gurol DT, Ogel K, Karadag F. Reliability and validity of Turkish Version the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES) in male substance dependent inpatients. Turk Psikiyatri Derg 2011;22:(Suppl. 1):70–1.
   Google Scholar
• Simpson D. A conceptual framework for drug treatment process and outcomes. J Subst Abuse Treat 2004;27(2):99–121. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med 2009;24(2):226–32. [CrossRef]
   PubMed Web of Science ®Google Scholar
• O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998; 105 (2): 100–5. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, Cunningham CO. Factors associated with complicated inductions. J Subst Abuse Treat 2010, 39(1):51–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med 2007;22(9):1325–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro- Donlan C, Samet JH, Alford DP. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med 2008;23(9):1393–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Vigezzi P, Guglielmino L, Marzorati P, Silenzio R, De Chiara M, Corrado F, et al. Multimodal drug addiction treatment: A field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. J Subst Abuse Treat 2006;31(1):3–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004;(3):CD002207.
   Google Scholar
• Centre for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. Substance Abuse and Mental Health Services Administration. DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
   Google Scholar
• Dunn KE, Sigmon SC, Strain EC, Heil SH, Higgins ST. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend 2011;119(1–2):1–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010;35(5):537–40. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Thomas CP, Reif S, Haq S, Wallack SS, Hoyt A, Ritter GA. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatr Serv 2008;59(8):909–16. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Evren EC, Er FO, Erkıran M, Çakmak D. Axis I psychiatric co-morbidity among treatment-seeking heroin dependents: it's relation with socio-demographic and substance use properties. Journal of Clinical Psychiatry 2002;5(2):92–104. (Turkish)
   Google Scholar
• Savant JD, Barry DT, Cutter CJ, Joy MT, Dinh A, Schottenfeld RS, Fiellin DA. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend 2013;127(1–3):243–7. [CrossRef]
   Web of Science ®Google Scholar
• Anton B, Leff P, Calva JC, Acevedo R, Salazar A, Matus M, Pavón L, et al. Endomorphin 1 and endomorphin 2 suppress in vitro antibody formation at ultra-low concentrations: anti-peptide antibodies but not opioid antagonists block the activity. Brain Behav Immun 2008;22(6):824–32. [CrossRef]
   Web of Science ®Google Scholar
• Heinzerling KG, McCracken JT, Swanson AN, Ray LA, Shoptaw SJ. COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J Clin Psychopharmacol 2012; 32(1):135–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Dreifuss JA, Griffin ML, Frost K, Fitzmaurice GM, Potter JS, Fiellin DA, et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend 2013;131(1–2):112–8. [CrossRef]
   Web of Science ®Google Scholar
• Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF 2000 cohort study. Addiction 2008;103(11):1828–36. [CrossRef]
   PubMed Web of Science ®Google Scholar